Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Agadjanyan
Institute for Molecular Medicine, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Institute for Molecular Medicine
Intellectual property rights (e.g., royalties, patents, copyrights) not from the awardee Institution
A patent that was licensed to Neuroimmune LLC is associated with continued research of grant project. The Board of Directors at IMM has approved on August 24, 2012 the request that Dr. Agadjanyan be appointed to a non-salaried supervisory position at Neuroimmune, LLC and he receive appropriate deferred compensation in shares. Currently, Neuroimmune LLC shares cannot be valued. The relationship between Dr. Agadjanyan and the IMM with Neuroimmune, LLC was approved and deemed appropriate as long as full disclosure and approval will be forthcoming of any change in status or change in agreements between Neuroimmune, LLC, Dr. Agadjanyan and/or IMM.
Combining AD Epitope Vaccine with Innate Immunity
The neuropathological features of AD include extracellular plaques (composed primarily of A?) and intracellular neurofibrillary tangles (composed primarily of a cytoskeletal protein, tau). Recent clinical studies using biomarkers demonstrated that A? abnormalities precede tau pathology and cognitive decline by 10 years or more, whereas accumulation of pathological tau correlates with the onset of clinical symptoms, so we hypothesize that targeting both biomarkers might be necessary for the prevention/inhibition of disease progression and cognitive decline. Thus, goals of this R01 proposal are (i) to test the efficacy of 3 vaccines (based on the universal and immunogenic MultiTEP platform) targeting pathological A?, tau or A? /tau simultaneously in 3xTg-AD mice possessing both A? and tau pathologies and (ii) to optimize the immunization regimen based on a combination of these prophylactic and therapeutic vaccines.
Filed on September 10, 2014.
Tell us what you know about Michael Agadjanyan's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.